Therapeutics targeting the epidermal growth factor receptor (EGFR) [14,15], which is often mutated in NSCLC tumors in patients of East-Asian origin [16] and female never smokers, vascular endothelial growth factor (VEGF) [17,18,19,20], anaplastic lymphoma kinase (ALK), and the programmed death protein 1 and programmed death ligand-protein 1 (PD-1/PD-L1) immune checkpoint [21] have increased the number of therapeutic options available for patients with advanced disease. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.